search
Back to results

Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial

Primary Purpose

Small Cell Lung Cancer, Limited Stage, Stage III Non-small Cell Lung Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Functional Lung Avoidance Thoracic Radiotherapy
Standard Thoracic Radiotherapy
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Small Cell Lung Cancer, Limited Stage focused on measuring Lung Cancer, Radiotherapy, Biomarkers, Radiation Lung Injury, Quality of Life

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Patients with a histologic diagnosis of non-small cell carcinoma or small cell carcinoma of lung
  2. Locally advanced stage III A or III B lung carcinoma according to American Joint Committee on Cancer (AJCC) 7th edition or highly selected patients with oligo-metastatic disease amendable for thoracic radiotherapy with curative intent
  3. Not undergoing radical surgical resection
  4. Patients do not have prior radiotherapy to the thorax
  5. Age ≥ 20 years
  6. Karnofsky performance status (KPS) ≥ 60%.
  7. Women of childbearing potential and male participants must practice adequate contraception
  8. Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent

Exclusion criteria:

  1. Prior radiotherapy to thorax
  2. Unable to receive assigned radiation dose due to normal lung constraint
  3. Inability to attend full course of radiotherapy or follow-up visits
  4. Presence of metastatic disease. Patients who present with oligo-metastatic disease where all metastases have been ablated (with surgery or radiotherapy) or in complete remission after systemic therapy are candidates if they are receiving radiotherapy to the thoracic disease with curative intent
  5. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:

    • Uncontrolled active infection requiring intravenous antibiotics at the time of registration
    • Transmural myocardial infarction ≤ 6 months prior to registration.
    • Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration.
    • Life-threatening uncontrolled clinically significant cardiac arrhythmias.
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
    • Uncontrolled psychiatric disorder.
  6. Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic.
  7. Pregnant or lactating women

Sites / Locations

  • National Taiwan University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Functional Lung Avoidance-TRT

Standard-TRT

Arm Description

Functional Lung Avoidance Thoracic Radiotherapy The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable

Standard Thoracic Radiotherapy The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging

Outcomes

Primary Outcome Measures

The pulmonary quality of life at 3 months post-radiotherapy
Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS)

Secondary Outcome Measures

Changes of pulmonary function test post-radiotherapy
Screening spirometry, diffusion capacity of lung for carbon monoxide
Patient reported outcome (Quality of Life questionnaire by Functional Assessment of Cancer Therapy)
Functional Assessment of Cancer Therapy-Lung
Patient reported outcome (Quality of Life questionnaire by EORTC Core)
EORTC Quality of Life-Core 30 questionnaire module
Patient reported outcome (Quality of Life questionnaire by EORTC Lung cancer)
EORTC Quality of Life questionnaire -Lung cancer 13
Acute toxicity
Common Toxicity Criteria for Adverse Events version 4
Late toxicity
Common Toxicity Criteria for Adverse Events version 4
Progression free survival
Number of participant without disease progression
Overall survival
Number of participant alive

Full Information

First Posted
June 27, 2016
Last Updated
March 7, 2019
Sponsor
National Taiwan University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03077854
Brief Title
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
Official Title
A Single-Blind Randomized Trial of Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Locally Advanced Non-Small Cell and Small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 2016 (undefined)
Primary Completion Date
May 2021 (Anticipated)
Study Completion Date
May 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Thoracic radiotherapy (TRT) is a standard curative treatment for locally advanced, unresectable non-small cell lung cancer (NSCLC) and limited stage small cell lung cancer (SCLC). TRT has been recognized to cause moderate to severe lung injury in a substantial portion of patients. Conventional standard curative TRT planning techniques minimize the radiation dose to the anatomical lungs, without adaption of regional pulmonary function variations. The principal investigator hypothesized that preferential avoidance of functional lung during curative TRT may decrease the risk of pulmonary toxicity. Functional lung regions are identified using four- dimensional computed tomography for ventilation imaging. This randomized, single-blind trial will comprehensively assess the impact of functional lung avoidance on pulmonary toxicity, quality of life, and clinical outcome in patients receiving curative TRT for locally advanced NSCLC and SCLC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Cell Lung Cancer, Limited Stage, Stage III Non-small Cell Lung Cancer
Keywords
Lung Cancer, Radiotherapy, Biomarkers, Radiation Lung Injury, Quality of Life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Functional Lung Avoidance-TRT
Arm Type
Experimental
Arm Description
Functional Lung Avoidance Thoracic Radiotherapy The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable
Arm Title
Standard-TRT
Arm Type
Active Comparator
Arm Description
Standard Thoracic Radiotherapy The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging
Intervention Type
Radiation
Intervention Name(s)
Functional Lung Avoidance Thoracic Radiotherapy
Intervention Description
Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed) Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed) Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions
Intervention Type
Radiation
Intervention Name(s)
Standard Thoracic Radiotherapy
Intervention Description
Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed) Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed) Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions
Primary Outcome Measure Information:
Title
The pulmonary quality of life at 3 months post-radiotherapy
Description
Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS)
Time Frame
Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months
Secondary Outcome Measure Information:
Title
Changes of pulmonary function test post-radiotherapy
Description
Screening spirometry, diffusion capacity of lung for carbon monoxide
Time Frame
At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy
Title
Patient reported outcome (Quality of Life questionnaire by Functional Assessment of Cancer Therapy)
Description
Functional Assessment of Cancer Therapy-Lung
Time Frame
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Title
Patient reported outcome (Quality of Life questionnaire by EORTC Core)
Description
EORTC Quality of Life-Core 30 questionnaire module
Time Frame
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Title
Patient reported outcome (Quality of Life questionnaire by EORTC Lung cancer)
Description
EORTC Quality of Life questionnaire -Lung cancer 13
Time Frame
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Title
Acute toxicity
Description
Common Toxicity Criteria for Adverse Events version 4
Time Frame
From date of radiotherapy until 90 days after radiotherapy starts
Title
Late toxicity
Description
Common Toxicity Criteria for Adverse Events version 4
Time Frame
90 days after radiotherapy starts until the date of death from any cause, up to 60 months
Title
Progression free survival
Description
Number of participant without disease progression
Time Frame
From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months
Title
Overall survival
Description
Number of participant alive
Time Frame
From date of enrollment until the date of death from any cause, assessed up to 60 months
Other Pre-specified Outcome Measures:
Title
Serum biomarkers in association with radiation pneumonitis
Description
Tumor necrosis factor-alpha, Transforming growth factor-beta concentration measured by ELISA
Time Frame
At baseline, 1, 2, 3, 4, 6 months post-radiotherapy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Patients with a histologic diagnosis of non-small cell carcinoma or small cell carcinoma of lung Locally advanced stage III A or III B lung carcinoma according to American Joint Committee on Cancer (AJCC) 7th edition or highly selected patients with oligo-metastatic disease amendable for thoracic radiotherapy with curative intent Not undergoing radical surgical resection Patients do not have prior radiotherapy to the thorax Age ≥ 20 years Karnofsky performance status (KPS) ≥ 60%. Women of childbearing potential and male participants must practice adequate contraception Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent Exclusion criteria: Prior radiotherapy to thorax Unable to receive assigned radiation dose due to normal lung constraint Inability to attend full course of radiotherapy or follow-up visits Presence of metastatic disease. Patients who present with oligo-metastatic disease where all metastases have been ablated (with surgery or radiotherapy) or in complete remission after systemic therapy are candidates if they are receiving radiotherapy to the thoracic disease with curative intent Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows: Uncontrolled active infection requiring intravenous antibiotics at the time of registration Transmural myocardial infarction ≤ 6 months prior to registration. Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration. Life-threatening uncontrolled clinically significant cardiac arrhythmias. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. Uncontrolled psychiatric disorder. Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic. Pregnant or lactating women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Feng-Ming Hsu, MD
Phone
+886-2-23123456
Ext
67061
Email
hsufengming@ntuh.gov.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Feng-Ming Hsu, MD
Organizational Affiliation
National Taiwan University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Feng-Ming Hsu, MD
Phone
+886-2-23123456
Ext
67061
Email
hsufengming@ntuh.gov.tw

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial

We'll reach out to this number within 24 hrs